Ieq Capital LLC Acquires New Position in Corcept Therapeutics Incorporated $CORT

Ieq Capital LLC acquired a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 92,394 shares of the biotechnology company’s stock, valued at approximately $8,034,000.

Other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Corcept Therapeutics during the 2nd quarter worth approximately $1,080,964,000. Parallel Advisors LLC lifted its holdings in shares of Corcept Therapeutics by 2.5% in the 1st quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock valued at $160,329,000 after buying an additional 96,763 shares during the period. State Street Corp lifted its holdings in shares of Corcept Therapeutics by 0.5% in the 4th quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock valued at $103,915,000 after buying an additional 15,656 shares during the period. Geode Capital Management LLC boosted its stake in shares of Corcept Therapeutics by 38.0% in the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after buying an additional 734,646 shares in the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Corcept Therapeutics by 213.5% in the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after buying an additional 1,480,059 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks sharply raised long-term earnings forecasts. The firm increased its FY2026 EPS estimate to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also raised, including Q1 2027 to $0.11 from a projected loss of $0.17 and Q2 2028 to $1.17 from $0.69. These revisions signal expectations for accelerating profitability.
• Positive Sentiment: Recent operating results provide support for the bullish outlook. Corcept’s latest reported quarter produced $0.36 in EPS versus the $0.02 consensus estimate, while revenue of $256.15 million exceeded expectations of $221.15 million and grew 31.7% year over year.
• Positive Sentiment: Analyst sentiment and price targets remain constructive. Recent coverage includes Buy or Overweight ratings and price targets ranging from $150 to $165, while the reported consensus rating is “Moderate Buy” with a $138.17 target. An investment analysis also argued that the launch of Lifyorli and continued Korlym growth could drive revenue growth, margin expansion and further EPS upside. Like The Knicks, Corcept Rebounded And Is Crushing It
• Neutral Sentiment: Zacks maintained a “Hold” rating. The improved earnings estimates are encouraging, but the unchanged rating suggests the analyst views the stock’s substantial rally and high valuation as partly reflected in the price.
• Negative Sentiment: Director David Mahoney sold 103,606 shares for approximately $12.25 million. The transaction reduced his ownership by 8.37%, although he still retained more than 1.13 million shares. The sale could create short-term sentiment pressure, but it does not necessarily indicate a change in the company’s fundamentals. Insider Selling: Corcept Therapeutics Director Sells Stock

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, Director James N. Wilson sold 10,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $111.43, for a total value of $1,114,300.00. Following the sale, the director owned 1,074,543 shares of the company’s stock, valued at approximately $119,736,326.49. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sean Maduck sold 3,664 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $114.49, for a total value of $419,491.36. Following the completion of the transaction, the insider owned 9,755 shares of the company’s stock, valued at approximately $1,116,849.95. This represents a 27.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 520,146 shares of company stock valued at $48,903,764 in the last 90 days. 20.70% of the stock is owned by corporate insiders.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $122.25 on Monday. The business’s 50 day simple moving average is $97.39 and its 200-day simple moving average is $64.76. The firm has a market capitalization of $13.22 billion, a price-to-earnings ratio of 291.08 and a beta of 0.45. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $123.44.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The business had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. During the same quarter in the prior year, the firm posted $0.29 EPS. The company’s revenue was up 31.7% compared to the same quarter last year. On average, equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.77 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on CORT shares. Canaccord Genuity Group upped their price objective on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Truist Financial started coverage on Corcept Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 target price for the company. HC Wainwright boosted their target price on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. UBS Group set a $135.00 price target on shares of Corcept Therapeutics in a research note on Thursday, May 28th. Finally, Weiss Ratings upgraded shares of Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $138.17.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.